Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial

Degaga TS., Pasaribu AP., Tripura R., Ghanchi N., Rajasekhar M., Adhikari B., Ley B., Bamboro SA., Jabbar FA., Hasibuan N., Tego TT., Zehra S., Qurashi B., Mnjala H., Lee G., Li P., Kazi AM., Safitri W., Yulita Y., Siagian DSP., Syahputra D., Hadi H., Muhammad T., Ibrahim A., Syed N., Dost K., Puspitrasari AM., Kariodimedjo PP., Rai A., Rumaseb A., Sutanto E., Ean M., Khan A., Sokha M., Commons RJ., Weston S., Noviyanti R., Peto T., Callery JJ., Ali U., Mehmood T., Dondorp A., Devine A., Setiawan E., Mwaura M., Cassidy-Seyoum S., Temesgen R., Abate DT., Erjabo EB., Gessa GG., Kiros FG., Usmani MI., Raza A., Woyessa A., Hailu A., Simpson JA., Karahalios A., Beg MA., von Seidlein L., Dysoley L., Auburn S., Price RN., Thriemer K.